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alvular Heart Disease and Pregnancy
art II: Prosthetic Valves
ri Elkayam, MD, FACC, Fahed Bitar, MD
os Angeles, California
A large number of prosthetic heart valves (PHV) are being implanted in patients with both
congenital and acquired valvular disease. Many of the recipients of such valves are women of
childbearing age who desire to have children. The main issues involved with pregnancy in a
patient with PHV include the selection of PHV in women during their childbearing age, risks
to both the mother and the fetus associated with pregnancy and the management of the
patients with PHV during gestation. (J Am Coll Cardiol 2005;46:403–10) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.087American College of Cardiology Foundation
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phe first successful replacement of heart valve in human was
eported in 1960 (1). Since then, prosthetic heart valves
PHV) have been developed into remarkably useful devices.
large number of PHVs are being implanted every year
round the world, and many of them in women of child-
earing age who desire to have children (2). There are three
ain issues related to PHV and pregnancy that will be
iscussed in this review: 1) selection of PHV in women of
hildbearing age who desire to become pregnant; 2) mater-
al and fetal risks associated with pregnancy in patients with
HV; and 3) the management of patients with PHV during
regnancy.
ELECTION OF PHV IN
OMEN OF CHILDBEARING AGE
selection of PHV in women during their childbearing
ge is still problematic, because an ideal valve is not
vailable. The two major groups of artificial heart valves
i.e., the mechanical prostheses and the bioprostheses)
oth provide advantages and limitations. Important areas
f difference are durability, incidence of thromboembo-
ism, valve hemodynamics, and effect on fetal outcome.
issue valves. Tissue valves (bioprostheses) can be sepa-
ated into three categories: heterografts, homografts, and
utografts. Most of the information regarding pregnancy in
omen with bioprosthetic valves has been obtained in
omen with porcine heterografts. The use of tissue valves
uring childbearing age reduces the risk of thromboembo-
ism and anticoagulation during pregnancy, but is associated
ith a high risk of structural valve deterioration (SVD) in
oung women. Patients between the age of 16 and 39 at the
ime of surgery, with either Hancock (Hancock Jaffe Lab-
ratories, Irvine, California) or Carpentier-Edwards porcine
ioprostheses (Edwards Lifesciences, Irvine, California),
emonstrated a high incidence of SVD, which became
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Manuscript received January 28, 2005; accepted February 8, 2005.ignificant as early as 2 to 3 years after surgery and was as
igh as 50% at 10 years and 90% at 15 years (3). Similarly,
amieson et al. (4) reported an increased rate of Carpentier-
dwards porcine bioprosthetic SVD in younger patients (27%
reedom from SVD at 10 years for patients30 years of age
ompared with 77% and 85% for patients between 30 and
9 years and 60 years, respectively). More recently, North
t al. (5) have reported valve loss at 10 years in 82% of 73
omen with a mean age of 23  6 years at the time of valve
eplacement with bioprosthetics of various types (Hancock,
arpentier-Edwards, Medtronic Intact [Medtronic, Min-
eapolis, Minnesota]). The risk of SVD was seven-fold
reater in the mitral than the aortic or tricuspid position.
hese data indicate that at least one-half of porcine hetero-
rafts implanted in young women of childbearing age can be
xpected to fail within 10 years after surgery, with higher
ikelihood of failure in patients with mitral bioprosthesis.
ecause women of childbearing age who receive biopros-
hetic valves are likely to need re-operation, the risk asso-
iated with a second surgery has to be considered when a
HV is being selected. Early mortality for re-operation in
uch patient populations has been reported to be 3.8% in one
tudy (6) and 8.7% in another (7).
The hemodynamic profile of the stented porcine hetero-
rafts is, in general, inferior to that of low profile mechanical
rostheses of comparable size (8). New bioprosthetic valves
ave been increasingly used in the aortic position and could
ossibly provide some advantages in young women. The
tentless porcine xenografts might provide superior hemo-
ynamic profile compared with stented porcine aortic het-
rografts, especially in patients with small aortic root (9).
he Carpentier-Edwards Pericardial (xenograft) valve
eems to have a better long-term durability than the porcine
ioprosthesis (10). In spite of the potential advantages of
hese new bioprosthetic valves, very little information is
vailable regarding their use in young women and in
regnant patients, and duration of follow-up in older
opulations is also limited.
Homograft (allograft) aortic valves offer some advantages
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Valvular Heart Disease and Pregnancy August 2, 2005:403–10hat include superior hemodynamics compared with stented
orcine valves and low thrombogenicity compared with
echanical valves (11). Because of low rate of infections,
hey are often used in patients with endocarditis (1).
lthough there is no proven benefit regarding patient
utcome and SVD with the use of homografts, a recent
etrospective study by North et al. (5) reported a superior
urability of homograft valves (n  72) compared with
ioprosthetic valves (n  73) in woman 12 to 35 years old
72% vs. 18% at 10 years, p  0.0001). In addition,
e-operation rate for SVD at 15 years with homograft valves
as reported to be 15% in patients age 21 to 40 years (11),
rate significantly lower than that reported in young women
ith porcine heterografts (3,4). Lund et al. (12) reported 25
ears’ experience (1969 to 1993) of primary aortic valve
eplacement with homografts in 618 non-pregnant patients
ith a mean age of 51 years. Thirty-day mortality was 5.0%,
rude survival at 10 and 20 years was 67% and 35%,
espectively, freedom from SVD was 62% and 18% and redo
alve replacement, 81% and 35%. Estimated 10- and 20-
ear freedom from SVD in a 30-year-old patient receiving a
omograft from a 30-year-old donor was 82% and 39%,
espectively. Only limited data, however, are available re-
arding outcome of pregnancy in women with aortic ho-
ografts (13–15). Sadler et al. (14) recently reported on 41
regnancies in 21 women after homograft valve replace-
ent. Of 32 pregnancies with known outcome, 94% had
ive births, and there was no preterm birth. Two women
eveloped cardiac failure during pregnancy, without evi-
ence of valve-related complications. Mortality after a
econd aortic valve homograft replacement was reported to
e 3.4% in 144 patients with a mean age of 49 years, and
reedom from re-operation was 97% and 82% at 5 and 10
ears, respectively (16).
The Ross procedure involves the removal of the patient’s
wn pulmonary valve and adjacent main pulmonary artery,
hich are used to replace the diseased aortic valve, usually
ith the neighboring aorta, and reimplantation of the
oronary arteries into the graft as well as the insertion of a
uman pulmonary or aortic homograft into the pulmonic
alve (17). This procedure is not thrombogenic and provides
xcellent valve hemodynamics (18) and has, therefore, been
ecommended by some authors as an attractive procedure
or aortic valve replacement in young women who wish to
ecome pregnant (1). The operation, however, is technically
ifficult, and associated mortality was reported between
Abbreviations and Acronyms
ACCP  American College of Chest Physicians
aPTT  activated partial thromboplastin time
LMWH  low molecular weight heparin
PHV  prosthetic heart valve
SVD  structural valve deterioration
UFH  unfractionated heparin.6% and 13% in earlier studies (19) and approximately w.0% in later studies (20,21). Information about pregnancy
n women after the Ross procedure is limited (22,23). The
nly follow-up longer than 10 years did not include preg-
ant women and showed, in 131 hospital survivors with a
ean age of 32 years, survival of 85% and 60% and freedom
rom any operation of 76% and 62% at 10 and 20 years,
espectively (24). The majority of re-operations were per-
ormed for severe valve regurgitation, and mortality associ-
ted with re-operation was 20% within one year of surgery.
ore and Somerville (22) reported on 14 pregnancies in
ight women who had undergone pulmonary autograft valve
eplacement. All women were in New York Heart Associ-
tion functional class I, had normal left ventricular function,
nd none required anticoagulation during pregnancy. Six
ad mild aortic regurgitation, three had mild pulmonary
egurgitation, and two had mild pulmonic stenosis. There
as no maternal death, thromboembolic event, hemorrhagic
omplications, or SVD during pregnancy.
oes pregnancy accelerate the rate of bioprosthetic
VD? A number of reports have provided a strong indica-
ion of pregnancy-related accelerated deterioration of tissue
alves. Hanania et al. (25) reported SVD and need for
e-operation in 7 of 74 bioprostheses exposed to pregnancy
n average of 5.9 years after the initial operation. An even
igher incidence was reported by Kadri et al. (26), who
escribed SVD in 4 of 14 patients; by Sbarouni et al. (27),
ho found SVD in 17 of 49 women, leading to valve
eplacement during pregnancy in 2 and postpartum in 13;
nd by Born et al. (28), who reported re-operation during
regnancy or the puerperium in 14% of 20 patients. Lee et
l. (29) reported SVD during pregnancy in only 4 out of 95
regnancies in 57 women with bioprosthetic valves, al-
hough a lower 10-year graft survival rate was noted in
omen with a history of two subsequent pregnancies after
heir valve replacement (17%), compared with only one
ubsequent pregnancy (55%). In addition, Badduke et al. (7)
tudied long-term performance of biological prostheses in
7 women35 years of age; 17 of these women experienced
7 pregnancies. Structural valve deterioration was reported
n 47% of patients with a history of pregnancy, compared
ith only 14% in the non-pregnant group (p  0.05).
e-operation, primarily due to SVD, which presented as
alcification and obstruction, was performed in 59% of the
regnancy group and 19% of the non-pregnancy group (p
.05). More recently, Sadler et al. (14) reported SVD that
ccurred during pregnancy in 10% of patients with mitral
ioprosthetic valves.
Although the previously mentioned reports make a strong
ase for pregnancy-related accelerated SVD of tissue valves,
ther reports have failed to support these findings. Avila et
l. (30) conducted a 5-year prospective follow-up of 48
atients with bioprosthetic valves who became pregnant and
7 comparable women who did not and found a comparable
ate of SVD (27% and 30%, respectively) and re-operation
8% in both groups). Jamieson et al. (6) compared 53
omen who experienced pregnancy and 202 women under
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August 2, 2005:403–10 Valvular Heart Disease and Pregnancyhe age of 35 years who did not. The rate of SVD and
alve-related operation at a mean follow-up of approxi-
ately seven years was slightly, but not significantly, higher
n the pregnancy group (51% vs. 41%, and 51% vs. 42%,
espectively). Similarly, Salazar et al. (31) reported deterio-
ation of bovine pericardial bioprostheses at a rate of 3.5%
er patient-year in 48 women who had 58 pregnancies,
hich was comparable to 3.4% per patient-year found in a
omparable control group of 107 patients. The actuarial
reedom from dysfunction was 77% at 8 years for the
regnancy group and 73% for the control group. In a Cox
roportional hazard regression analysis, pregnancy did not
nfluence SVD.
In summary, deterioration of bioprosthetic heart valves
uring pregnancy has been reported in several studies, but
ould not be confirmed by others. Although most available
ata might support an accelerated SVD of bioprosthetic
alves during pregnancy, this could simply reflect the
ell-established deterioration of tissue valves in young
ndividuals.
echanical prostheses. Mechanical PHV are classified into
hree major groups: caged-ball, tilting-disc, and bileaflet
alves (1). The most widely employed mechanical valves are
urrently the bileaflet valves (St. Jude valve). The old-
eneration Bjork Shiley valve, a tilting-disc prosthesis no
onger used in the U.S., and the Starr-Edwards caged-ball
alve, the oldest PHV in continuous use, have an historical
mportance and were extensively used in women of child-
earing age and during pregnancy (5,25,27–29).
Mechanical PHVs, including those in the smaller sizes
8), offer excellent long-term durability (32) and superior
emodynamic profile; however, their thrombogenicity and
eed for life-long anticoagulation are associated, during
regnancy, with a risk of thromboembolism and maternal
leeding. In addition, available information on fetal out-
ome suggests an increased risk of fetal loss as well as
rematurity, low birth weight, birth defects, and neonatal
ortality (14,25,27,28,33) in patients with mechanical
HVs, most probably due to the mandatory use of antico-
gulation.
ummary and recommendation. The selection of PHV
or women of childbearing age remains difficult and needs to
e individualized. The bileaflet mechanical valves provide a
uperb record of durability, excellent hemodynamic profile,
nd relatively small risk of thromboembolic and bleeding
omplications with careful anticoagulation. Because dura-
ility is a major factor in young patients, these valves seem
o be a reasonable choice for women who are compliant and
ommitted to the rigor of continuous and careful anticoag-
lation. In women who are not interested in anticoagulation
r for whom close follow-up is not possible, a tissue valve is
referred. In the aortic position, homografts, pericardial
alves, and stentless porcine xenografts have not been
xtensively used in pregnancy, but seem to offer better
emodynamics and possibly better long-term durability
homograft) than stented porcine heterografts. The pulmo- oary autograft (Ross procedure) is associated with a very low
ncidence of thromboembolism and also seems to provide
emodynamic and possibly durability benefit compared with
he standard porcine valve, but is associated with higher rate
f SVD and need for re-operation compared with the
ew-generation mechanical prostheses. Because of the com-
lexity of the operation, only experienced surgeons should
erform it.
reconception evaluation and consultation. The risk of
omplications during pregnancy in a patient with PHV
epends on type, position, and function of the valve as well
s cardiac function, patient symptoms, and functional ca-
acity. Pregnancy evaluation should include a careful history
nd physical examination as well as an echo-Doppler study
o evaluate cardiac and valvular function. Exercise testing,
ncluding the determination of maximum oxygen consump-
ion, can provide an objective estimation of functional
apacity. The patient and her family should be advised on
otential complications that might occur during pregnancy,
ncluding: hemodynamic and symptomatic worsening;
igher incidence of thromboembolism; deterioration of
ioprosthetic valves; and potential harm to the fetus due to
ardiac medications, including anticoagulation (increased
ate of fetal loss, prematurity, and fetal growth retardation).
ecause clinical deterioration often occurs during preg-
ancy, patients with marked impairment of left ventricular
nd/or valvular function that are moderately or severely
ymptomatic (class III and IV) should be advised against
regnancy.
ANAGEMENT OF COMPLICATIONS
eart failure. Physiological hemodynamic changes during
regnancy might result in cardiac decompensation in pa-
ients with PHV, especially those with left ventricular
ysfunction and small valve sizes. In addition, increased
ncidence of arrhythmias during pregnancy (34) might also
ead to hemodynamic and symptomatic deterioration. Al-
hough most patients who are asymptomatic or only mildly
ymptomatic before conception tolerate the hemodynamic
urden of pregnancy, decreased functional capacity, the
evelopment of pulmonary edema, and even death have
een reported (14,27,28,35–37). The treatment of heart
ailure in patients with PHV depends on its cause. Safe
rugs include digoxin, diuretics, nitrates, hydralazine, and
eta blockers. In contrast, angiotensin-converting enzyme
nhibitors and angiotensin receptor antagonist are contrain-
icated, and amiodarone as well as sodium metroprusside
hould be avoided (38).
alve thrombosis. Pregnancy is associated with an in-
reased incidence of thromboembolism due to a hypercoag-
lable state. Available reports have described thromboem-
olic events in 7% to 23% (average 13%) of patients,
ne-half of them with valve thrombosis (14,25,27–29,31).
lthough this complication is more likely in patients with
lder-generation valves (Bjork-Shiley, Starr-Edwards) in
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Valvular Heart Disease and Pregnancy August 2, 2005:403–10he mitral position, thrombosis of newer-generation me-
hanical PHV, including in the aortic position, have been
eported (39–45). Recent guidelines for management of
HV thrombosis recommend thrombolysis as a first-line
reatment if there are no contraindications (46). Heparin
ight be used initially for small non-obstructive thrombi,
articularly if thrombolysis is contraindicated (47). This
herapy has been shown to achieve hemodynamic success,
hich has been similar across valves, in 85% of the cases.
verall complications, including peripheral embolization
nd bleeding, were reported in 18% and death in 5.6% (48).
lthough pregnancy has been perceived as a contraindica-
ion to thrombolytic treatment (49), this therapy has been
sed in pregnant women for various indications (25,27,
9,45,50–57). Thrombolysis was effective and safe in most
atients; however, failure of therapy, leading to death
45,56), bleeding (45,50,57), and embolic complications
39) has been reported during pregnancy. Because of the
igh risk of fetal loss during pregnancy (58), surgery should
e reserved for patients in whom thrombolysis is contrain-
icated (50), might be associated with high risk of compli-
ations, or has been ineffective.
nticoagulation. The risk associated with pregnancy in
omen with mechanical PHV is related mainly to the
ncreased incidence of thrombosis due to pregnancy-related
ypercoagulability. Effective anticoagulation, therefore, is
ritical in patients with mechanical PHV, but remains
roblematic because both oral anticoagulation and heparins
ave been associated with important fetal and maternal side
ffects (33).
Decisions on the choice of anticoagulation should be
ade by both physicians and patients, who need to be fully
nformed of the potential risks and benefits associated
ith the various therapeutic options. The American
eart Association/American College of Cardiology Task
orce report in 1998 (59) (Table 1) recommended the use of
arfarin, especially in high-risk women, through week 35,
hen unfractionated heparin (UFH) should be substituted,
n anticipation of labor. These recommendations also rec-
gnized that the risk of warfarin embryopathy was unac-
eptable to many women and suggested an alternative
reatment with heparin, intravenously during the first tri-
ester. More recent recommendations, published in 2004
s part of the seventh American College of Chest Physicians
ACCP) consensus on antithrombotic therapy (60) (Table
), include one of three regimens: 1) aggressive adjusted-
ose of low molecular weight heparin (LMWH) through-
ut pregnancy; 2) adjusted-dose of UFH, throughout preg-
ancy; or 3) use of either LMWH or UFH between 6 and
2 weeks and close-to-term only and the use of warfarin at
ther times; the use of warfarin during the first trimester
as not recommended. Our recommended regimen (Table
) combines the two aforementioned recommendations and,
n addition, differentiates between patients at higher and
ower risk and emphasizes the importance of monitoring
rough level of heparin in addition to peak levels (61). TThromboembolic prophylaxis in high-risk patients
older-generation PHV in the mitral position, atrial fibril-
ation, history of thromboembolism while receiving antico-
gulation) seems to be best achieved with oral anticoagula-
ion for the first 35 weeks (Tables 1 and 3). Because
regnancy is associated with increased risk, a target inter-
ational normalized ratio of 3.0 (2.5 to 3.5) should be
chieved (60). Exposure to warfarin during the first 8 to 12
eeks of gestation, however, is associated with high inci-
ence of fetal loss, mostly due to spontaneous abortion, and
f warfarin embryopathy (33). The reported incidence of
arfarin embryopathy has varied and has been a subject of
ebate (62,63). Although recent authoritative text has esti-
ated the incidence of warfarin embryopathy to be as low as
.6% of live births (1), one recent review indicated an
ncidence of 6.4% (33), and another review indicated 7.4%
64). Furthermore, these reviews probably represent an
nderestimation, due to the retrospective nature and lack of
athological assessment of the aborted fetuses in most series
64). This assumption is supported by a prospective study
eporting facial defects suggestive of warfarin embryopathy
n 29% of viable offspring (65) and two recent retrospective
tudies reporting skeletal deformity and nasal hypoplasia in
0% of babies exposed to warfarin (14,66). A recent study
as suggested that warfarin risk was dose related and
ccurred mostly in women taking a daily dose 5 mg (67).
able 1. ACC/AHA Recommendation for Anticoagulation
uring Pregnancy in Patients With Mechanical
rosthetic Valves
1. The decision whether to use heparin during the first trimester or to
continue oral anticoagulation throughout pregnancy should be made
after full discussion with the patient and her partner; if she chooses to
change to heparin for the first trimester, she should be made aware
that heparin is less safe for her, with a higher risk of both thrombosis
and bleeding, and that any risk to the mother also jeopardizes the
baby.
2. High-risk women (a history of thromboembolism or an older-
generation mechanical prosthesis in the mitral position) who choose
not to take warfarin during the first trimester should receive
continuous unfractionated heparin intravenously in a dose to prolong
the mid-interval (6 h after dosing) activated partial thromboplastin
time to 2 to 3  control value. Transition to warfarin can occur
thereafter.
3. In patients receiving warfarin, the international normalized ratio
should be maintained between 2.0 and 3.0 with the lowest possible
dose of warfarin, and low-dose aspirin should be added.
4. Women at low risk (no history of thromboembolism, newer low-
profile prosthesis) might be managed with adjusted-dose subcutaneous
heparin (17,500 to 20,000 U twice daily to prolong the mid-interval
(6 h after dosing) activated partial thromboplastin time to 2 to 3 
control value.
5. Warfarin should be stopped no later than week 36 and heparin
substituted in anticipation of labor.
6. If labor begins during treatment with warfarin, a cesarean section
should be performed.
7. In the absence of significant bleeding, heparin can be resumed 4–6 h
after delivery, and warfarin begun orally.
eprinted, with permission, from Bonow et al. (59).
ACC  American College of Cardiology; AHA  American Heart Association.his finding, however, could not be confirmed by another
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August 2, 2005:403–10 Valvular Heart Disease and Pregnancytudy, which showed a high rate of fetal loss regardless of
arfarin dose (13). Use of warfarin during pregnancy might
lso be associated with fatal hemorrhage in the fetus and
entral nervous system abnormalities (68). In addition, a
ong-term follow-up has shown an increase in minor neu-
ologic dysfunction and low IQ (80) in school-age chil-
ren with a history of prenatal warfarin exposure (69).
Because of high incidence of premature labor in women
ith PHV (36,70), warfarin should be substituted with
eparin at the 35 to 36 gestational weeks to avoid labor
hile patients are receiving warfarin therapy. Because anti-
oagulated preterm infants are at increased risk for intracra-
ial hemorrhage during both vaginal and C-section delivery
71), earlier change to heparin should be considered in
omen at high likelihood for premature delivery (previous
reterm delivery, shortened and dilated cervix, cardiac
urgery during pregnancy, and multiple gestations).
Heparin is an alternative therapy in women who elect to
void treatment with warfarin during the first trimester.
nitiation of heparin before the sixth gestational week can
arkedly reduce warfarin-induced fetal loss and prevent
arfarin embryopathy (33). To ensure adequacy of antico-
gulation during the change from warfarin to heparin, it
hould be done in the hospital with adequate monitoring.
able 2. Recommendations of the Seventh ACCP Consensus
onference on Antithrombotic Therapy for Prophylaxis in
atients With Mechanical Heart Valves
1. Aggressive adjusted-dose UFH, given every 12 h subcutaneously
throughout pregnancy; mid-interval activated partial thromboplastin
time maintained at 2  control levels, or anti-Xa heparin level
maintained at 0.35 to 0.70 IU/ml.
OR
2. LMWH throughout pregnancy, in doses adjusted according to weight
or as necessary to maintain a 4-h postinjection anti-Xa heparin level
of about 1.0 IU/ml.
OR
3. UFH or LMWH, as above, until the 13th week; change to warfarin
until the middle of the third trimester, then restart UFH or LMWH
therapy until delivery.
eprinted, with permission, from Bates et al. (60).
ACCP  American College of Chest Physicians; LMWH  low molecular
eight heparin; UFH  unfractionated heparin.
able 3. Recommended Approach for Anticoagulation Prophylax
Higher Risk
irst generation PHV (e.g., Starr-Edwards, Bjork Shiley)
in the mitral position, atrial fibrillation, history of TE on
anticoagulation
Se
arfarin (INR 2.5–3.5) for 35 weeks, followed by UFH
(mid-interval aPTT 2.5) or LMWH (pre-dose anti-Xa 0.7)
 ASA 80–100 mg q.d.
SC
OR
FH (aPTT 2.5–3.5) or LMWH (pre-dose anti-Xa 0.7) for
12 weeks, followed by warfarin (INR 2.5–3.5) to 35th week,
then UFH (aPTT 2.5) or LMWH (pre-dose anti-Xa 0.7)
 ASA 80–100 mg q.d.
SC
eprinted, with permission, from Elkayam et al. (61).
aPTT  activated partial thromboplastin time; ASA  acetylsalicylic acid; INR  inte
thromboembolism; other abbreviations as in Table 2.wo retrospective surveys conducted in Europe and a
rospective study performed in Mexico reported a high
ncidence of valve thrombosis in patients with old-
eneration mechanical PHVs treated with subcutaneous
FH (25,27,36). Although the clinical implications of these
ndings are questionable (72), owing to lack of information
elated to the level of anticoagulation and its monitoring,
hese reports might suggest resistance to moderate doses of
FH in high-risk women with old-generation PHV. For
his reason, a high heparin dose should be used (7,500 to
0,000 U every 12 h) (72) and adjusted to a mid-interval
ctivated partial thromboplastin time (aPTT) ratio of 2.5
control value. Continuous intravenous heparin might
rovide a consistent therapeutic level and is preferred over
ubcutaneous administration (Table 1). At the same time,
nfection of the central line and even endocarditis are
otential complications (73). Because of the relative short
uration of effect of subcutaneous UFH, pre-dose aPTT
hould be measured to determine a possible need for
very-eight-h dosing to prevent subtherapeutic levels.
Low molecular weight heparin has been recommended as
n alternative to UFH (60). Low molecular weight heparin
oes not cross the placental barrier (74) and it offers
otential advantages (74,75), including fewer bleeding com-
lications, a lower frequency of heparin-induced thrombo-
ytopenia (although incidence of heparin-induced throm-
ocytopenia seems to be rare in pregnancy [76]), a lower
ncidence of osteoporosis, superior subcutaneous absorption
nd bioavailability, a longer half-life, more predictable dose
esponse, and a lower rate of spontaneous abortion in
atients with PHV compared with UFH (77). Recent
eview of 81 pregnancies in 75 women with mechanical
HVs treated with LMWH during pregnancy (77) reported
n 8.6% rate of valve thrombosis. Although this seemingly
igh incidence of thrombotic events could reflect a biased
eporting of cases with complications, it raised a concern
egarding the safety of the drug and resulted in a warning by
LMWH manufacturer regarding their use in patients with
echanical PHV (78). A careful review of the reported
ases, however, indicated that most, if not all of these cases
Women With PHV During Pregnancy
Lower Risk
generation PHV (e.g., St. Jude Medical, Medtronic-Hall) and any
anical PHV in the aortic postion
H (mid-interval aPTT 2.0–3.0) or LMWH (pre-dose anti-Xa 0.6) for
eeks, followed by warfarin (INR 2.5–3.0) for 35 weeks, then SC UFH
-interval aPTT 2.0–3.0) or LMWH (pre-dose anti-Xa level 0.6)
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Valvular Heart Disease and Pregnancy August 2, 2005:403–10ere associated with an inadequate dose, lack of monitor-
ng, or subtherapeutic anti-Xa levels (40 – 43,61,63,
7,79,80). Among 51 pregnancies whose anti-factor Xa
evels were monitored, only one patient was reported to have
hromboembolic complication (77). A recent review has
oncluded that all three anticoagulation options have been
nder-studied and that LMWH could be the best available
ption (79). More recently (80), the earlier warning by the
MWH manufacturer has been rephrased to “use of
ovenox for thromboprophylaxis in pregnant women with
echanical PHV has not been adequately studied.” How
hould anticoagulation with LMWH be monitored? Be-
ause of an increased and changing dose requirement in
regnancy, administration of LMWH on the basis of
eight alone is inadequate, and measurement of anti-Xa
ctivity is necessary to ensure effective anticoagulation (81).
he most recent ACCP recommendations call for the use of
MWH at a dose aiming to achieve peak (4-h post-
njection) anti-factor Xa levels of around 1.0 U/ml. Recent
ork by Barbour et al. (81), however, has clearly demon-
trated that such peak levels were associated with subthera-
eutic trough levels of 0.5 U/ml in the great majority of
ases. These data, in addition to documented risk of valve
hrombosis with subtherapeutic pre-dose anti-Xa levels,
uggest the importance of routine measurement and main-
enance of trough levels at therapeutic range (0.6 to 0.7
/ml) in the highly thrombogenic population of pregnant
omen with mechanical PHV (Table 3). Peak levels should
lso be monitored to prevent excessive anticoagulation (i.e.,
1.5 U/ml), in which case, an 8-hourly rather than a
2-hourly dosing should be used. To ensure patient com-
liance and adequate prophylaxis, anti-factor Xa activity or
partial thromboplastin time should be measured at least
very two weeks. Catheter placement for epidural anesthesia
s not advisable within 10 to 12 h of the last dose, because
f longer half-life of LMWH (82). For this reason, and to
revent spinal or epidural hematoma, LMWH should be
ithdrawn 18 to 24 h before an elective delivery and
ubstituted with intravenous UFH. Because of the potential
dded benefit (83), a small dose of aspirin (60 to 150
g/day), which is safe during pregnancy (84), might be
dded in high-risk patients to further reduce the incidence
f thromboembolism.
In summary, the choice of anticoagulation in pregnant
atients with PHV needs to be made after detailed discus-
ion with the patient and her family. Potential risks and
enefits of available therapeutic options and the fact that
vailable data are insufficient to reliably predict efficacy and
afety need to be emphasized. Clinical experience, however,
trongly suggests that the risk of anticoagulation is greatly
elated to inadequate dosing and monitoring and can be
inimized by a strong commitment to a strict therapeutic
egimen and a close follow-up by both the patient and her
hysician.
2eprint requests and correspondence: Dr. Uri Elkayam, Heart
ailure Program, Keck School of Medicine, Los Angeles County/
niversity of Southern California Medical Center, Room 7621,
200 North State Street, Los Angeles, California 90033. E-mail:
lkayam@usc.edu.
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